Comparative Pharmacology
Head-to-head clinical analysis: ACTIDIL versus DESLORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIDIL versus DESLORATADINE.
ACTIDIL vs DESLORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1-receptor antagonist; competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, blocking histamine-induced bronchoconstriction, vasodilation, and increased capillary permeability.
Desloratadine is a long-acting tricyclic histamine antagonist selective for the H1 receptor, inhibiting histamine release from mast cells and basophils. It reduces allergic inflammation by decreasing cytokine and chemokine release.
2.5 mg orally every 4 to 6 hours as needed; maximum 10 mg per day.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
Clinical Note
moderateDesloratadine + Venlafaxine
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Venlafaxine."
Clinical Note
moderateDesloratadine + Nefazodone
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Nefazodone."
Clinical Note
moderateDesloratadine + Stiripentol
"The risk or severity of adverse effects can be increased when Desloratadine is combined with Stiripentol."
Clinical Note
moderateTerminal half-life 27 hours (range 21–30 h) in healthy adults; supports once-daily dosing.
Renal excretion of unchanged drug and metabolites accounts for approximately 60-80% of the administered dose; biliary/fecal elimination comprises the remainder (20-40%).
Primarily renal (87% as metabolites, ~41% unchanged) and fecal (~9%). Metabolized to active 3-hydroxydesloratadine.
Category C
Category A/B
Antihistamine
Antihistamine
Desloratadine + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Desloratadine."